Market Opportunity

T-cell Immunotherapy Revolutionizing Cancer Care

The first T-cell based immunotherapy received FDA approved in 2017 for B-cell lymphoma based on the Chimeric Antigen Receptor T-cell (CAR-T) technology, T-cell immunotherapy has evolved from the initial focus on blood malignities to solid cancers with great promise.

In Feb 2024, the first TIL-based drug was approved for metastatic (stage IV) Melanoma. In the years to come polyclonal TIL and targeted TCR-T protocols are expected to reach the market for several of the large solid cancer types.

TILs Lead the Way in Targeting Solid Cancers

TILs have emerged as a transformative approach in cancer treatment. Initially recognized for their natural ability to target tumors, TIL therapies have advanced significantly with next-generation innovations improving their scalability and effectiveness, particularly for solid tumors. As research and clinical applications progress, TILs are positioned to play a leading role in the future of personalized cancer medicine, offering durable treatment options with potential for great impact.

At CuraCell, we specialize in TIL-based therapies while recognizing the complementary potential of TCR-T and CAR-T technologies in addressing diverse cancer challenges in generating effective and durable cancer therapies.

Advancing Cancer Therapy

At CuraCell we are at the forefront of transforming cancer therapy by focusing on cancers with solid tumors: these account for the majority of malignancies worldwide. Solid cancers, unlike haematological cancers, present unique challenges due to their complex microenvironments, physical barriers, and ability to evade immune detection.

We have compelling proof points from patient-named treatments demonstrating the efficacy and precision of our TIL-based product: CC-38

With the innovative expansion platform CytoPLY^TM, we can target a broad spectrum of solid cancers, including those with limited treatment options. We aim to bring hope to those battling cancers when existing therapy is not enough.

CuraCell’s starting point is to target colorectal and prostate cancer. Colorectal cancer is the second deadliest cancer in the US (both genders combined). Prostate cancer is the most common cancer type among men and the second deadliest.